These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 10335104)
21. Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen. Landay AL; Spritzler J; Kessler H; Mildvan D; Pu M; Fox L; O'Neil D; Schock B; Kuritzkes D; Lederman MM; J Infect Dis; 2003 Nov; 188(10):1444-54. PubMed ID: 14624369 [TBL] [Abstract][Full Text] [Related]
22. Switch study of nevirapine. AIDS Patient Care STDS; 2000 Dec; 14(12):672. PubMed ID: 11187109 [No Abstract] [Full Text] [Related]
23. Considerations on the effectiveness of nevirapine in protease inhibitor-based regimen simplification. Martínez E; Gatell JM AIDS; 2007 Aug; 21(13):1829-30. PubMed ID: 17690588 [No Abstract] [Full Text] [Related]
24. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. Bartlett JA; Fath MJ; Demasi R; Hermes A; Quinn J; Mondou E; Rousseau F AIDS; 2006 Oct; 20(16):2051-64. PubMed ID: 17053351 [TBL] [Abstract][Full Text] [Related]
25. [Antiretroviral therapy in patients infected with HIV-1]. Corti ME Medicina (B Aires); 1998; 58 Suppl 1():49-56. PubMed ID: 9674248 [No Abstract] [Full Text] [Related]
26. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. Murphy RL; Sommadossi JP; Lamson M; Hall DB; Myers M; Dusek A J Infect Dis; 1999 May; 179(5):1116-23. PubMed ID: 10191212 [TBL] [Abstract][Full Text] [Related]
27. HIV drug now approved for use with protease inhibitors. Nurse Pract; 1998 Oct; 23(10):89. PubMed ID: 9805335 [No Abstract] [Full Text] [Related]
28. Nevirapine--first of a new class of drugs. PI Perspect; 1996 Sep; (No 19):9-10. PubMed ID: 11363907 [TBL] [Abstract][Full Text] [Related]
29. Effect of highly active antiretroviral therapy on recurrent oropharyngeal candidiasis in HIV-infected patients. Revankar SG; Sanche SE; Dib OP; Caceres M; Patterson TF AIDS; 1998 Dec; 12(18):2511-3. PubMed ID: 9875598 [No Abstract] [Full Text] [Related]
31. Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors. Tavel JA; Miller KD; Masur H Clin Infect Dis; 1999 Mar; 28(3):643-76. PubMed ID: 10194094 [No Abstract] [Full Text] [Related]
32. [Pharma-clinics. The drug of the month. Nevirapine. Viramune]. Nkoghe D; Léonard P; Moutschen M; Demonty J Rev Med Liege; 1999 Dec; 54(12):948-51. PubMed ID: 10686802 [TBL] [Abstract][Full Text] [Related]
34. HIV/AIDS management in office practice. Antiretroviral therapy. Hartman AF Prim Care; 1997 Sep; 24(3):531-60. PubMed ID: 9271691 [TBL] [Abstract][Full Text] [Related]
35. Antiviral update. PI Perspect; 1996 Nov; (No 20):8-9. PubMed ID: 11363972 [TBL] [Abstract][Full Text] [Related]
36. [Infections with human immunodeficiency viruses. Part II: Antiretroviral drugs, therapeutic options, and diagnostics]. Stock I Med Monatsschr Pharm; 2011 Jul; 34(7):234-44; quiz 245-6. PubMed ID: 21809598 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients. Fätkenheuer G; Römer K; Kamps R; Salzberger B; Burger D AIDS; 2001 Nov; 15(17):2334-5. PubMed ID: 11698713 [No Abstract] [Full Text] [Related]
38. Efficacy of nevirapine-based HAART in HIV-1-infected, treatment-naive persons with high and low baseline viral loads. Raffi F; Reliquet V; Podzamczer D; Pollard RB HIV Clin Trials; 2001; 2(4):317-22. PubMed ID: 11590534 [TBL] [Abstract][Full Text] [Related]
39. Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study. De Luca A; Baldini F; Cingolani A; Di Giambenedetto S; Zaccarelli M; Tozzi V; Ammassari A; Murri R; Antinori A AIDS; 2000 Jul; 14(11):1655-6. PubMed ID: 10983653 [No Abstract] [Full Text] [Related]
40. Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies. Wood E; Hogg RS; Heath KV; de la Rosa R; Lee N; Yip B; O'Shaughnessy MV; Montaner JS AIDS; 2003 Dec; 17(18):2629-34. PubMed ID: 14685057 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]